WASHINGTON, June 19, 2017 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today that Jeffrey Stein, Ph.D., Chairman of AWG and President and Chief Executive Officer of Cidara Therapeutics, Inc. (Nasdaq: CDTX), Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS, Inc. (Nasdaq: SCYX), and Robert Schotzinger, M.D., Ph.D., President and Chief Executive Officer of Viamet Pharmaceuticals, Inc. will be participating in an interactive panel discussion at the 2017 BIO International Convention, taking place June 19-22 in San Diego, CA. The panel titled, "Antifungus Among Us: Recognizing Vulnerability and Opportunity with the Next-Generation of Antifungals" will focus on the growing global public health epidemic caused by fungal infections and highlight the urgent needs and development opportunities in the space.
Details for the panel session are as follows:
Session Title: Antifungus Among Us: Recognizing Vulnerability and Opportunity with the Next-Generation of Antifungals
Session ID: 22252
Date and time: Tuesday, June 20, 2017, at 4:15 p.m. PT
Location: San Diego Convention Center, Room 9, Upper Level
- Jeffrey Stein, Ph.D., President and Chief Executive Officer, Cidara Therapeutics
- Marco Taglietti, M.D., President and Chief Executive Officer, SCYNEXIS
- Robert Schotzinger, M.D., Ph.D., President and Chief Executive Officer, Viamet Pharmaceuticals
- Tom Chiller, M.D., M.P.H., Chief, Mycotic Diseases Branch, Centers for Disease Control and Prevention (CDC)
- Tim Cooke, Ph.D., Chief Executive Officer, Novadigm Therapeutics
About Cidara Therapeutics
Cidara is a clinical-stage biotechnology company focused on developing new anti-infectives that have the potential to transform the standard of care and save or improve patients' lives. The company is currently advancing its novel echinocandin antifungal, CD101 IV, through Phase 2 and developing CD201, its bispecific antibiotic immunotherapy, for the treatment of multi-drug resistant Gram-negative bacterial infections. CD101 IV has improved pharmacokinetics compared to existing echinocandins and has the potential for expanded utility across patient settings. CD101 IV is the only once-weekly product candidate in development for the treatment and prevention of life-threatening invasive fungal infections. CD201 is the first drug candidate selected from Cidara's novel Cloudbreak™ platform, the first immunotherapy discovery platform designed specifically to create compounds that direct a patient's immune cells to attack and eliminate bacterial, fungal or viral pathogens. Cidara recently received a grant for up to $6.9 million from CARB-X (Combating Antibiotic Resistant Bacteria Accelerator) to advance the development of CD201. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas. The Company's lead product candidate, SCY-078, is the first representative of a novel intravenous and oral triterpenoid antifungal family and is in Phase 2 clinical development for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. For more information, please visit www.scynexis.com.
Viamet discovers and develops breakthrough therapies based on our leadership in metalloenzyme chemistry and biology. The Company's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. Viamet also leverage its metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. Focusing on the needs of patients and clinicians, Viamet designs drug candidates to achieve superior efficacy and safety profiles compared to currently marketed drugs. For more information, please visit www.viamet.com.
About The Antimicrobials Working Group
AWG was founded in 2012 with the vision of utilizing collective power to improve the regulatory, investment, and commercial environment for emerging antibiotics and antifungal companies. Today, AWG is comprised of thirteen antimicrobials companies: Amplyx Pharmaceuticals, Arsanis Inc., Cempra Inc., Cidara Therapeutics Inc., ContraFect Corporation, Iterum Therapeutics Ltd., Melinta Therapeutics Inc., Nabriva Therapeutics US Inc., Paratek Pharmaceuticals Inc., SCYNEXIS Inc., Theravance Biopharma U.S. Inc., Viamet Pharmaceuticals Inc., and Zavante Therapeutics Inc. For more information, please visit www.antimicrobialsworkinggroup.org.
About The Conafay Group:
The Conafay Group is a life-sciences government relations firm based in Washington D.C. that serves as Washington counsel and coalition manager for AWG, led by Stephen R. Conafay, Principal. For more information, please visit www.conafaygroup.com.
SOURCE Antimicrobials Working Group (AWG)